THE APEX TIMES
Norton Cancer Research Institute is among five hospitals nationwide testing a device designed to check white blood cell counts without drawing blood, a change supporters say could mean fewer trips to the hospital for certain patients.
A Louisville woman who says she has battled cancer three times in the last three years is helping Norton Cancer Research Institute test technology intended to check a key blood marker without a traditional blood draw. WAVE reported that Barbara Cook is participating in the Norton study as part of a broader, multi-hospital effort that could alter how clinicians monitor patients during treatment.
According to WAVE, Norton Cancer Research Institute is one of five hospitals nationwide testing the device. The technology is designed to assess white blood cell counts, an important clinical measurement used to track how a patient’s immune system is responding and how they may tolerate certain cancer therapies.
WAVE said the aim of the test is to spare some patients at least one additional hospital visit. In many cancer care plans, clinicians schedule follow-up blood work to confirm whether patients are safe to receive treatment or whether treatment timing should be adjusted based on lab results. By checking the counts without drawing blood, the device could reduce logistical burdens for patients and caregivers.
Cook’s involvement reflects how patients can contribute to research that seeks to streamline routine monitoring. WAVE identified her as a Louisville resident and described her cancer history as part of the background for why the technology matters to her and to others managing frequent clinical appointments.
The report places Norton’s research activity within a national trial framework, meaning data from multiple sites could be aggregated to evaluate whether the device works reliably in real-world clinical settings. While the study is focused on white blood cell counts, WAVE’s reporting also framed the broader goal as reducing the number of steps and visits that can interrupt treatment schedules.
As the trial proceeds, Norton and partner hospitals will continue testing the device against established clinical expectations for accuracy and usability, WAVE reported. If the technology performs as intended, it could inform how future cancer monitoring is handled at hospitals that currently rely on blood draws for lab-based measurements.
For patients, the practical benefit highlighted by WAVE is less time spent traveling for routine testing and fewer encounters associated with blood draws, particularly for people already managing repeated treatment appointments. The study’s next steps will depend on trial results and how clinicians decide the device fits into existing monitoring workflows.
Comments
Community guidelines. Comments may be removed for violations.
Loading comments...